Using 68Ga-FAPI PET-CT for diagnosing metastatic tumors and treating them with 177Lu-EB-FAPI
Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI
This study is testing a new treatment for patients with metastatic tumors to see if a special imaging technique can help find the tumors and if the treatment can effectively target and shrink them.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05400967 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the safety and therapeutic response of a novel treatment, 177Lu-EB-FAPI, in patients with metastatic tumors. It utilizes 68Ga-FAPI PET-CT imaging to identify tumors that express fibroblast activation protein (FAP), which is overexpressed in many cancers. The treatment involves administering 177Lu-EB-FAPI, a modified therapeutic agent designed to enhance drug retention in tumor cells. The study will assess both the diagnostic capabilities of the imaging technique and the effectiveness of the new therapy in targeting metastatic tumors.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed treated or untreated metastatic tumors who have undergone recent PET/CT scans.
Not a fit: Patients who are pregnant, breastfeeding, or have medical conditions that may interfere with study compliance will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a more effective treatment option for patients with metastatic tumors.
How similar studies have performed: While the use of FAPI in imaging has been successful in various cancers, the specific combination of 177Lu-EB-FAPI for therapy is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * confirmed treated or untreated metastatic tumors patients; * 68Ga-FAPI PET/CT and 18F-FDG PET/CT within two weeks; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhaohui Zhu
- Email: 13611093752@163.com
- Phone: 86-13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.